Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...
Starboard Value 13Ds are worth paying attention to. The hedge fund, led by manager Jeff Smith, is one of the most prolific -- and successful -- activist funds. Since 2011, Starboard has filed 305 activist reports: 47 initial 13Ds and 258 13D/A SEC...
On December 27, 2018, Cannell Capital LLC — a hedge fund based in Alta, Wyoming – disclosed sending three separate letters to three company managements, notifying them of Cannell’s activist intentions. Buying the stocks targeted by Cannell on that date would have produced an average gain of 32.40% over the 25 trading days since.
Activist Cannell Capital raised its stake in Lee Enterprises (LEE) to 7.37%. The hedge fund filed a 13D/A on July 30 disclosing a 1.7 million additional share purchase of the newspaper publisher. Cannell is now LEE's largest shareholder. Lee Enterprises owns 49...
Hudson Executive Capital disclosed on Monday that it bought 143,200 shares of USA Technology (USAT) at $4.46 along with call options giving the fund the right to buy another 1,250,000 shares of stock at $10. The call options expire on Jan. 17, 2020.
Starboard Value cut its Cars.com stake aggressively after the online auto retailer's strategic search failed and the company announced disappointing Q2 results. In a 13D/A filing submitted Wednesday afternoon, the hedge fund disclosed selling 4.47 million shares of the online automobile retailer on August 5-6 at...
A Mellanox (MLNX) insider bought $2.2 million of the Israeli chip designer as fears China will block a proposed merger with Nvidia Corp (NVDA) pushed the price of MLNX well below the buyout price. Stephen Sanghi, a director of Sunnyvale-based Mellanox since February...
Engine Capital filed a 13D targeting PDL BioPharm (PDLI) on Wednesday morning, disclosing a 5.28% stake in the Nevada-based healthcare stock. Engine also disclosed it sent a letter to PDLI's board saying the fund "invested in PDLI because of the significant intrinsic value attributable to...
Engine Capital filed a 13D on Cymabay (CBAY) two weeks after the development stage biotech company halted a trial of its leading drug candidate causing it's shares to fall as much as 75%. In a 13D filing Thursday evening, New York-based Engine Capital, L.P....
Macerich insiders have bought a record $2.8 million of the retail mall developer's stock over the last two months as Macerich (MAC) shares hit seven year lows. A great story needs a great title. And what could be better than "Retail Apocalypse" to capture...